Adherence to oral therapies among patients with renal cell carcinoma: Post hoc analysis of the ECOG‐ACRIN E2805 trial
| Autor: | Naomi B. Haas, Janice P. Dutcher, David E. Gerber, Hannah Fullington, Robert S. DiPaola, Maneka Puligandla, Caitlin C. Murphy, Isaac Alex Bowman |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Sorafenib renal cell carcinoma Cancer Research medicine.medical_specialty Adolescent Administration Oral urologic and male genital diseases Placebo law.invention Young Adult Double-Blind Method Randomized controlled trial law Internal medicine Post-hoc analysis medicine Humans Radiology Nuclear Medicine and imaging adherence Carcinoma Renal Cell Research Articles RC254-282 Aged Aged 80 and over Sunitinib business.industry Clinical Cancer Research Neoplasms. Tumors. Oncology. Including cancer and carcinogens clinical trial Middle Aged Rash Kidney Neoplasms Clinical trial Treatment Outcome Oncology Pill medicine.symptom business Research Article medicine.drug |
| Zdroj: | Cancer Medicine, Vol 10, Iss 17, Pp 5917-5924 (2021) Cancer Medicine |
| ISSN: | 2045-7634 |
| Popis: | Background As use of oral cancer therapies increases, patient adherence has become critical when evaluating the effectiveness of therapy. In a phase III trial for renal cell carcinoma, we: (a) characterized adherence to sorafenib, sunitinib, and/or placebo and (b) identified factors associated with non‐adherence. Methods ECOG‐ACRIN E2805 was a double‐blind, placebo‐controlled, randomized trial comparing adjuvant sorafenib or sunitinib in patients with resected primary renal cell carcinoma at high risk for recurrence. We used patient‐completed pill diaries to measure adherence as the number of pills taken divided by the number of pills prescribed. Log‐binomial regression was used to identify correlates of non‐adherence ( In a randomized clinical trial for renal cell carcinoma, adherence to oral therapy was lower (85%) than adherence to placebo (95%). Adherence was also worse among racial/ethnic minorities, patients experiencing certain toxicities, and high volume enrolling sites, highlighting several challenges to address in clinical practice as oral therapies become increasingly common. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|